IDEA Collider: Innovation & Asymmetric Learning in Pharma
IDEA Pharma
All episodes
Best episodes
Seasons
Top 10 IDEA Collider: Innovation & Asymmetric Learning in Pharma Episodes
Goodpods has curated a list of the 10 best IDEA Collider: Innovation & Asymmetric Learning in Pharma episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to IDEA Collider: Innovation & Asymmetric Learning in Pharma for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite IDEA Collider: Innovation & Asymmetric Learning in Pharma episode by adding your comments to the episode page.
IDEA Collider | Dr Peter Bach
IDEA Collider: Innovation & Asymmetric Learning in Pharma
09/01/20 • 59 min
Peter B. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year.
In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer. Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered.
Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006. Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes. View a comprehensive list of media coverage of Dr. Bach and his work. Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008. In 2020, Dr. Bach co-founded EQRx, a biotechnology startup focused on developing affordable drugs. He currently serves an advisory role within the organization.
Further information at: https://drugpricinglab.org/about/ or https://www.mskcc.org/news/media-coverage?keys=Peter+bach
IDEA Collider | Kabir Nath
IDEA Collider: Innovation & Asymmetric Learning in Pharma
08/26/21 • 52 min
Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences.
For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business.
Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.
IDEA Collider | Dan Skovronsky
IDEA Collider: Innovation & Asymmetric Learning in Pharma
05/24/21 • 49 min
Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development. Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994..
IDEA Collider | Nick Wood, Benji Compston
IDEA Collider: Innovation & Asymmetric Learning in Pharma
02/11/21 • 42 min
Syn is an award winning music agency and creative solutio, providing music strategy, composition, sound design and sonic branding for advertising, cinema and television, as well as music supervision, licensing and music curation services and our studios record voiceover, ADR and narration.
In this interview, we discuss the user experience (patient, physician), via sound, for healthcare and pharma environments
More information at https://syn.world
IDEA Collider | Riccardo Zacconi
IDEA Collider: Innovation & Asymmetric Learning in Pharma
01/26/21 • 42 min
Great interview with Riccardo on CNBC
Find out more about PTEN Research at https://www.ptenresearch.org
IDEA Collider | John Tsai, MD
IDEA Collider: Innovation & Asymmetric Learning in Pharma
01/18/21 • 45 min
Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com
IDEA Collider | Andy Coravos and Jen Goldsack, The DiMe Society Playbook
IDEA Collider: Innovation & Asymmetric Learning in Pharma
12/07/20 • 45 min
A discussion of The Playbook, from DiMe Society, Digital Clinical Measures
Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health
https://playbook.dimesociety.org
More on Andy (Andrea) Coravos here: http://www.andreacoravos.com
More on Jen (Jennifer) Goldsack here: https://en.wikipedia.org/wiki/Jennifer_Goldsack
More on DiMe Society here: https://www.dimesociety.org
IDEA Collider | Jen Horonjeff
IDEA Collider: Innovation & Asymmetric Learning in Pharma
08/25/20 • 46 min
In conversation, discussing patient input into clinical programs, unmet need assessments, measurement and so much more.
Jen was diagnosed with juvenile arthritis as an infant and now has a laundry list of other conditions and surprises (like a brain tumor). She is passionate about elevating and valuing the patient voice, and went on to become a health outcomes researcher, human factors engineer, FDA Consumer Representative, and, most importantly, a patient advocate. Jen earned a PhD in Environmental Medicine from NYU, and studies patient-centered outcomes at Columbia University Medical Center. Jen can usually be found dodging NYC traffic on her bicycle, sitting next to you at a conference, or rocking out to '90s music - she does a sweet running man.
Jen at IDEA's UnHerd event at 2020 JP Morgan
https://medium.com/@jhoronjeff
https://techcrunch.com/2020/02/14/this-co-op-wants-to-put-money-back-into-patients-hands/
IDEA Collider | Carinne Brouillon, Edward Hæggström, Rob Scott | Pharma Innovation Summit
IDEA Collider: Innovation & Asymmetric Learning in Pharma
11/30/20 • 46 min
Carinne Brouillon is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit
Professional milestones
- 2018 – 2019 Global Head of Therapeutic Areas, Boehringer Ingelheim
- 2014 – 2018 Head of Global Commercial Strategy Neuroscience at Janssen, Johnson & Johnson’s Pharmaceutical Company
- 2012 – 2018 President of Janssen Therapeutics and Member of the Janssen North America Leadership Team
Edward Hæggström Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015.
Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology.
Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.
Rob Scott, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. During his career he has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Before retiring, his most recent position was Chief Medical Officer and Head of Development at AbbVie where he had oversight on all early and late-stage development programs. He was also responsible for a team of over 4,000 employees spanning 52 countries, a budget of close to $2 billion and programs involving approximately 40 new molecular entities. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen where he was responsible for the development of evolocumab (Repatha) the first approved PCSK9 inhibitor, ivabradine (Corlanor), to treat heart failure and omecamtiv mecarbil, a direct myosin activator for heart failure. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies. Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He is a board member of Transclerate and a member of the PhRMA R&D Leadership Forum.
Embracing Innovation and Collaboration in the Pharma Industry with Dr. Nedim Pipic
IDEA Collider: Innovation & Asymmetric Learning in Pharma
06/14/23 • 39 min
Welcome to another episode of Idea Collider with your host, Mike Rea.
In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics.
Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape.
Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future.
Chapter Summaries
[0:00:21] Introduction to today's guest, Dr. Nedim Pipic
[0:04:23] Discussion on Innovation and Growth Mindset
[0:06:44] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health
[0:08:25] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs
[0:14:39] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms
[0:16:39] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture
[0:18:52] Discussion on Innovation and R&D in Pharmaceutical Industry
[0:20:22] Driving Innovation and Culture in a Private Pharmaceutical Company
[0:23:41] Insights on Innovation and Transformation
[0:25:46] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation
[0:27:04] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation
[0:33:28] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration
[0:36:06] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability
[0:37:39] Closing Remarks
Don't forget to Like, Share, Subscribe, Rate, and Review!
Keep up with Dr. Nedim Pipic;
● LinkedIn: https://www.linkedin.com/in/nedim-pip...
● Website: http://www.boehringer-ingelheim.com
Follow Mike Rea On;
● Website: https://www.ideapharma.com/
● Twitter:
Show more best episodes
Show more best episodes
FAQ
How many episodes does IDEA Collider: Innovation & Asymmetric Learning in Pharma have?
IDEA Collider: Innovation & Asymmetric Learning in Pharma currently has 55 episodes available.
What topics does IDEA Collider: Innovation & Asymmetric Learning in Pharma cover?
The podcast is about Life Sciences, Book Club, Pharma, Marketing, Podcasts, Science, Business and Innovation.
What is the most popular episode on IDEA Collider: Innovation & Asymmetric Learning in Pharma?
The episode title 'Embracing Innovation and Collaboration in the Pharma Industry with Dr. Nedim Pipic' is the most popular.
What is the average episode length on IDEA Collider: Innovation & Asymmetric Learning in Pharma?
The average episode length on IDEA Collider: Innovation & Asymmetric Learning in Pharma is 49 minutes.
How often are episodes of IDEA Collider: Innovation & Asymmetric Learning in Pharma released?
Episodes of IDEA Collider: Innovation & Asymmetric Learning in Pharma are typically released every 11 days, 1 hour.
When was the first episode of IDEA Collider: Innovation & Asymmetric Learning in Pharma?
The first episode of IDEA Collider: Innovation & Asymmetric Learning in Pharma was released on Sep 10, 2019.
Show more FAQ
Show more FAQ